United Therapeutics stock maintains Buy rating at H.C. Wainwright amid patent case developments

Investing.com - H.C. Wainwright has reiterated its Buy rating and $500.00 price target on United Therapeutics Corp. (NASDAQ:UTHR), currently trading at $432.66, as the company navigates ongoing patent litigation with Liquidia. The company maintains an "EXCELLENT" financial health score according to InvestingPro analysis.

Judge Andrews requested on September 24 that both United Therapeutics and Liquidia submit letters by October 1 outlining their positions on whether the Bayer v. Mylan decision affects their current patent dispute.

The Bayer v. Mylan case specifically addresses the claim term "clinically proven effective" and whether such functional language can impart patentability, with the Federal Circuit ruling that even if limiting, such functional language failed to establish patentability.

H.C. Wainwright consulted with a patent attorney who believes the Bayer decision likely has minimal impact on the United Therapeutics v. Liquidia case, suggesting Judge Andrews requested the companies’ positions to prevent potential remand issues during appeal.

The firm maintains its positive outlook on United Therapeutics with its $500 price target unchanged despite these ongoing legal proceedings.

In other recent news, United Therapeutics has been the focus of several analyst updates and projections. UBS raised its price target on the company to $580, maintaining a Buy rating, although it slightly adjusted its revenue forecast for Tyvaso in the third quarter of 2025. TD Cowen reiterated its Buy rating and a $500 price target following the presentation of full Phase III Tyvaso TETON-2 data at a conference, noting strong interest in the treatment for idiopathic pulmonary fibrosis (IPF). RBC Capital initiated coverage with an Outperform rating and a $569 price target, recognizing United Therapeutics as a leader in rare lung diseases. UBS also maintained its Buy rating with a $560 price target, highlighting a potential $3-4 billion peak sales opportunity for Tyvaso. Cantor Fitzgerald significantly increased its price target to $525, citing a "best-case TETON-2 readout" and raising the probability of success for Tyvaso in IPF to 90%.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.